Market Overview

UPDATE: Citigroup Initiates Coverage on The Medicines Company with Neutral Rating, $27 PT

Share:
Related MDCO
Citi Sees Limited Sales For Blood-Clot Drug At The Medicines Company
FDA Advisory Committee Recommends Approval of The Medicines Company's Antiplatelet Therapy Cangrelor

In a report published Friday, Citigroup initiated coverage on The Medicines Company (NASDAQ: MDCO) with a Neutral rating and $27.00 price target.

Citigroup noted, “We are cautious on the ability of MDCO's pipeline to replace the >90% of total revenues represented by Angiomax before the drug's 2019 loss of exclusivity. Based on our research and physician checks, we question whether the cumulative opportunities for Cleviprex, cangrelor, and oritavancin would be sufficient to offset the revenue gap, even assuming cangrelor and oritavancin are ultimately approved. In the interim, remaining patent litigation and pivotal readouts from Angiomax's competitors present risks to nearer-term cash flows. We are initiating with a Neutral/High Risk rating and $27 price target.”

The Medicines Company closed on Thursday at $23.07.

Latest Ratings for MDCO

DateFirmActionFromTo
May 2015Leerink SwannMaintainsOutperform
May 2015JP MorganMaintainsOverweight
Apr 2015CitigroupMaintainsNeutral

View More Analyst Ratings for MDCO
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Initiation Analyst Ratings

 

Related Articles (MDCO)

Around the Web, We're Loving...

Get Benzinga's Newsletters